Drug Trial Radar · NCT04152486
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
Last checked: Nov 19, 2026Latest source record: Nov 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20,426
Actual
Start
Nov 14, 2019
Primary completion
Jan 31, 2022
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Epicentre; Ministère de la Santé de la RDC; Médecins Sans Frontières, France; Coalition for Epidemic Preparedness Innovations; Janssen Vaccines & Prevention B.V.; Public Health England
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.
Conditions
- Ebola Virus Disease
Interventions
Ad26.ZEBOV, MVA-BN-Filo vaccineBiological
Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®. MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers and odds of vaccination status in Ebola Virus Diseases cases and in EVD-negative controls.Time frame: Through study completion, an average of 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
L'Institut National de Recherche Biomédicale RDC
Kinshasa, Democratic Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.